KLF10/KLF11 Antibody

What are the primary applications for KLF10/KLF11 antibodies in research?

KLF10/KLF11 antibodies are primarily utilized in immunohistochemistry (IHC) and enzyme-linked immunosorbent assay (ELISA) applications. According to available product data, these antibodies are recommended at specific dilutions: 1:50-1:100 for IHC and 1:5000 for ELISA applications . Some antibodies may also be suitable for Western blotting, though optimal conditions should be determined empirically for each application. These antibodies serve as essential tools for investigating KLF10/KLF11 expression patterns in various tissues and experimental models.

What species reactivity can be expected with KLF10/KLF11 antibodies?

Most commercially available KLF10/KLF11 antibodies demonstrate reactivity across human, mouse, and rat samples . This cross-species reactivity reflects the evolutionary conservation of these transcription factors and makes these antibodies versatile tools for comparative studies across mammalian models. When planning experiments with other species, cross-reactivity should be validated through proper controls before proceeding with full-scale studies.

What is the appropriate storage and handling for KLF10/KLF11 antibodies?

KLF10/KLF11 antibodies are typically shipped at 4°C and should be aliquoted upon receipt to prevent repeated freeze-thaw cycles. For long-term storage, antibodies should be kept at -20°C . Most formulations contain preservatives such as sodium azide (0.02%) and stabilizers like glycerol (50%) and BSA (0.5%) . To maintain antibody integrity, it's advisable to avoid more than 3-5 freeze-thaw cycles and to keep working aliquots at 4°C for short-term use.

What forms of KLF10/KLF11 antibodies are available for research?

These antibodies are predominantly available as rabbit polyclonal antibodies in liquid form . The antibodies are typically generated against synthetic peptides derived from human KLF10/KLF11 sequences, including specific regions such as the C-terminal region (for TIEG-1/2) or amino acids 391-440 . They are usually unconjugated, though secondary antibody options include AP, biotin, FITC, and HRP conjugates for detection flexibility in various experimental platforms .

How can researchers distinguish between KLF10 and KLF11 in experimental systems?

Distinguishing between KLF10 and KLF11 presents a significant challenge due to their structural similarities as members of the transforming growth factor-β-inducible early genes subfamily . While some antibodies target both proteins, researchers requiring specific detection should:

• Use epitope mapping to identify unique regions between KLF10 and KLF11

• Perform pre-absorption controls with recombinant KLF10 and KLF11 proteins

• Validate with genetic models (knockdown/knockout) of either protein

• Consider complementary techniques such as RT-qPCR for transcript-level validation

• Use ChIP-seq approaches with validated antibodies to distinguish binding patterns

The specificity challenge stems from the high homology between the C-terminal zinc finger domains of these proteins, making careful validation essential for conclusive results.

What are optimal experimental designs for ChIP assays using KLF10/KLF11 antibodies?

For successful chromatin immunoprecipitation (ChIP) experiments with KLF10/KLF11 antibodies, researchers should implement the following protocol considerations:

• Crosslinking optimization: Use 1% formaldehyde for 10-15 minutes at room temperature

• Sonication parameters: Optimize to achieve fragments of 200-500bp

• Antibody selection: Use ChIP-validated antibodies with confirmed specificity

• Controls: Include:

  • Input control (pre-immunoprecipitation chromatin)

  • IgG control (non-specific antibody)

  • Positive control (known target gene)

  • Negative control (non-target region)

• Detection method: qPCR primers should be designed to flank known or predicted KLF binding sites

Research has successfully employed this approach to identify KLF10 binding sites in metabolic pathways, particularly in liver tissue from diet-induced obese mice . For comprehensive binding site identification, ChIP followed by next-generation sequencing (ChIP-seq) has been successfully implemented using peak detection algorithms with cutoff values of 90-15% and false discovery rate scores <0.2 .

How can researchers investigate protein-protein interactions involving KLF10/KLF11?

Several methodologies have proven effective for studying KLF10/KLF11 protein interactions:

• GST pulldown assays: Using GST fusion proteins with in vitro translated proteins to identify direct interactions

• Co-immunoprecipitation: Detecting endogenous interactions with antibodies against KLF10/KLF11 and potential binding partners

• Yeast two-hybrid screening: Identifying novel interaction partners, as demonstrated for the TRD3 domain of KLF11

• Protein arrays: Complementary to yeast two-hybrid for validating interactions across protein domains

Research has successfully identified interactions between KLF11's TRD3 domain and proteins containing WD40, WWI, WWII, and SH3 domains using these combined approaches . When investigating the A347S genetic variant associated with MODY7, these methods revealed differential binding with co-factors that explained altered transcriptional activity.

What approaches can address non-specific binding in KLF10/KLF11 antibody applications?

Non-specific binding represents a common challenge when working with transcription factor antibodies. Researchers should implement the following strategies:

• Blocking optimization: Test different blocking agents (BSA, milk, serum) at various concentrations

• Antibody titration: Establish a signal-to-noise curve to determine optimal concentration

• Pre-absorption controls: Pre-incubate antibody with immunizing peptide to confirm specificity

• Alternative fixation methods: Compare different fixatives for IHC applications

• Validate with genetic approaches: Use tissues/cells with genetic manipulation of KLF10/KLF11 expression

Evidence for successful antibody validation comes from immunohistochemical analyses where pre-incubation of the antibody with the immunizing peptide effectively eliminated signal in human brain tissue sections, confirming specificity .

What are the critical considerations for immunohistochemistry with KLF10/KLF11 antibodies?

For optimal IHC results with KLF10/KLF11 antibodies, researchers should consider:

• Tissue preparation: Paraffin-embedded tissues require proper antigen retrieval

• Antigen retrieval method: Heat-induced (citrate buffer, pH 6.0) or enzymatic methods should be evaluated

• Antibody concentration: Initial testing at 1:50-1:100 dilution with optimization

• Detection system: Highly sensitive detection systems (e.g., polymer-based) may be beneficial

• Controls: Include positive control tissues with known expression and negative controls (primary antibody omitted)

Successful IHC application has been demonstrated in human brain tissue, where specific nuclear staining patterns were observed and confirmed through appropriate controls .

How can KLF10/KLF11 antibodies be utilized to study metabolic disorders?

KLF10 and KLF11 have established roles in metabolic regulation, with KLF11 mutations implicated in MODY7 and neonatal diabetes . Research approaches include:

• Tissue-specific expression: Using antibodies to map expression changes in diabetic vs. normal tissues

• Target gene regulation: Combining ChIP with expression analysis to identify regulated metabolic genes

• Genetic variant analysis: Comparing wild-type KLF11 with variants like A347S using co-IP and functional assays

• Animal models: Studying KLF10's protective role against metabolic dysfunction-associated steatohepatitis (MASH) in diet-induced obese mice

The A347S variant affects a transcriptional regulatory domain (TRD3) in KLF11, altering protein-protein interactions and consequently affecting the regulation of metabolic genes . Similar approaches can be applied to study KLF10's protective role against MASH in experimental models .

What methodological approaches can overcome detection challenges for low KLF expression levels?

When KLF10/KLF11 expression is low, researchers can implement these signal enhancement strategies:

• Signal amplification systems: Tyramide signal amplification or polymer-based detection

• Tissue/cell enrichment: Laser capture microdissection to isolate specific cell populations

• Concentration techniques: Protein concentration before Western blotting

• Alternative detection methods: RNA-level analysis (RT-qPCR) as complementary approach

• Induction experiments: Using TGF-β stimulation to increase expression, as KLF10 and KLF11 are rapidly expressed following TGF-β signal induction

How are KLF10/KLF11 antibodies utilized in studying transcriptional networks?

KLF10 and KLF11 function within complex transcriptional networks, particularly in metabolic regulation:

• Genome-wide binding studies: ChIP-seq approaches have identified binding sites within promoters of metabolic genes

• Co-regulator analysis: Antibodies against KLF10/KLF11 and potential co-regulators like Sin3a, HP1α, and CBP in sequential ChIP experiments

• Pathway integration: Investigating the relationship between TGF-β signaling and KLF10/KLF11-mediated transcription

• Cross-talk with other transcription factors: Co-immunoprecipitation to detect interactions with other metabolic regulators

Research has demonstrated that KLF11 regulates the expression of metabolic genes through interactions with proteins containing specific domains (WD40, WWI, WWII, and SH3), and genetic variants like A347S can disrupt these interactions .

What role do KLF10/KLF11 antibodies play in investigating cell cycle regulation?

KLF10 has demonstrated cell cycle regulatory properties, with implications for cellular proliferation control:

• Expression timing: Using antibodies to track expression changes during cell cycle progression

• Target identification: ChIP approaches to identify cell cycle-related target genes

• Interaction studies: Co-IP to identify interactions with cell cycle regulators

• Localization studies: Immunofluorescence to track subcellular localization throughout the cell cycle

Recent findings on the Drosophila homolog Cabut suggest conserved cell cycle regulatory functions that extend to mammalian KLF10 and KLF11, which are rapidly expressed following TGF-β signaling induction . This evolutionary conservation suggests fundamental roles in proliferation control that merit further investigation using antibody-based approaches.

How can advancements in recombinant antibody technology be applied to KLF10/KLF11 research?

While current commercial antibodies are primarily polyclonal, emerging recombinant antibody technologies offer several advantages:

• Increased specificity: Monoclonal or recombinant antibodies with defined epitope binding

• Reproducibility: Eliminating batch-to-batch variation inherent in polyclonal antibodies

• Engineered properties: Customized fragments for specialized applications

• Differential epitope targeting: Developing antibodies that can distinguish between KLF10 and KLF11

Future directions include developing recombinant antibodies against specific domains, such as the TRD3 domain of KLF11 that contains the A347S variant associated with MODY7 , to enable more precise investigations of protein-protein interactions and transcriptional regulation.